Macrocycles have demonstrated repeated success when addressing targets that have proved to be highly challenging for standard small-molecule drug discovery, especially in modulating macromolecular ...
The startup is developing macrocyles, which share strengths of both small molecules and biologics, as oral medicines against ...
Orbis Medicines secures €90M Series A to develop innovative oral macrocycles, offering cost-effective alternatives to ...
Orbis Medicines, an oral macrocycle drug discovery company, closed a €90 million Series A funding round, bringing the total ...
Huang Wu and the late J. Fraser Stoddart of the University of Hong Kong along with Wenping Hu and Yu Wang of Tianjin University led the effort to make and characterize the snub cube supramolecules.
Orbis Medicines Raises EUR 90 Million Series A Funding Round to Develop Pipeline of Oral Macrocycles
Orbis Medicines is focused on pioneering a new era for oral macrocycle drug discovery. Macrocycles are a large and diverse family of compounds with highly desirable therapeutic properties but ...
Financing to support the development of Orbis' pipeline of next-generation macrocycles, nCycles, with an initial focus on valida ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback